Nivalis Therapeutics
Developing a novel class of disease modifying therapies for patients with cystic fibrosis.
Launch date
Employees
Market cap
-
Enterprise valuation
$120—180m (Dealroom.co estimates Nov 2014.)
Boulder Colorado (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$10.0m | Series B | ||
| N/A | $30.0m | Series B | |
| N/A | N/A | IPO | |
N/A | Acquisition | ||
| Total Funding | $40.0m | ||